Tradipitant

Tradipitant
Clinical data
Trade namesNereus
Other namesVLY-686, LY686017
AHFS/Drugs.comnereus
License data
Routes of
administration		By mouth
Drug classNeurokinin NK1 antagonist
ATC code
  • None
Legal status
Legal status
Identifiers
  • (2-(1-(3,5-Bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H16ClF6N5O
Molar mass587.91 g·mol−1
3D model (JSmol)
  • Clc1ccccc1C(=O)c2c(nccc2)c3nnn(c3c4ccncc4)Cc5cc(cc(c5)C(F)(F)F)C(F)(F)F
  • InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
  • Key:CAVRKWRKTNINFF-UHFFFAOYSA-N

Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness).[1] It is a neurokinin 1 receptor antagonist.[1] It works by blocking substance P, a small signaling molecule.[1] VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.[2]

Tradipitant was approved for medical use in the United States in December 2025.[3]

Medical uses

Tradipitant is indicated for the prevention of vomiting induced by motion.[1]

Society and culture

Tradipitant was approved for medical use in the United States in December 2025.[4]

Names

Tradipitant is the international nonproprietary name.[5]

Tradipitant is sold under the brand name Nereus.[1]

References

  1. ^ a b c d e f https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220152Orig1s000lbl.pdf
  2. ^ "Company Overview of Eli Lilly & Co., Worldwide License to Develop and Commercialize VLY-686". Bloomberg Business. Retrieved 16 November 2015.
  3. ^ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 2 January 2026. Retrieved 10 January 2026.
  4. ^ "Vanda Pharmaceuticals Announces FDA Approval of Nereus (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness" (Press release). Vanda Pharmaceuticals. 30 December 2025. Retrieved 10 January 2026 – via PR Newswire.
  5. ^ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 73". WHO Drug Information. 29 (1). 2015. hdl:10665/331088.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.